← Leaderboards
Ravi K Amaravadi
University Of Pennsylvania
$13,477,656
Attributed
$14,771,277
Total exposure
12
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.9M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$26,084,659 · 13
By mechanism
P50$15,202,717 · 4
R01$6,101,192 · 3
P01$2,317,612 · 2
R21$1,036,915 · 1
P30$739,748 · 2
K23$686,475 · 1
Top collaborators
- Meenhard Herlyn5 shared
- Aaron Robert Goldman4 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Charles P Emerson$35,198,488
- Qin Yu$7,039,104
- Amos B Smith$26,356,961
- Meenhard Herlyn$50,214,821
- Aaron Robert Goldman$1,293,622
Others in their field
Top investigators on “Clinical Trials”
- Lawrence Corey · Fred Hutchinson Cancer Center$824,102,536
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$622,583,125
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,008,718
- Bambra Strokes · Ppd Development Lp$526,656,217
- Judith S. Currier · University Of California Los Angeles$504,273,077
Research focus
Clinical TrialsMalignant NeoplasmsResistanceAutophagocytosisTargeted TreatmentMelanomaInhibition Of AutophagyTumorPre-ClinicalPathway InteractionsFutureInstitutionResearch PersonnelResponseCellsImmunotherapyHydroxychloroquineBraf GeneNeoplastic CellRefractoryAntineoplastic AgentsChloroquineSignal TransductionInhibitor/Antagonist
Grant awards (57)
SPORE in Skin Cancer$2,351,294
P50 · FY2025 · CA
Resistance mechanisms to autophagy-modulating therapies$654,428
R01 · FY2025 · CA · contact PI
Targeting autophagy to enhance immune checkpoint inhibition$483,579
P50 · FY2025 · CA · contact PI
SPORE in Skin Cancer$2,257,242
P50 · FY2024 · CA
Resistance mechanisms to autophagy-modulating therapies$621,660
R01 · FY2024 · CA · contact PI
Targeting autophagy to enhance immune checkpoint inhibition$464,236
P50 · FY2024 · CA · contact PI
SPORE in Skin Cancer$2,186,705
P50 · FY2023 · CA
Resistance mechanisms to autophagy-modulating therapies$641,245
R01 · FY2023 · CA · contact PI
Targeting PPT1 in the Tumor Microenvironment$481,705
P01 · FY2023 · CA · contact PI
Targeting autophagy to enhance immune checkpoint inhibition$449,729
P50 · FY2023 · CA · contact PI
Cancer Therapeutics Program$83,257
P30 · FY2023 · CA · contact PI
SPORE in Skin Cancer$2,194,229
P50 · FY2022 · CA
Resistance mechanisms to autophagy-modulating therapies$669,910
R01 · FY2022 · CA · contact PI
Targeting PPT1 in the Tumor Microenvironment$480,986
P01 · FY2022 · CA · contact PI
Targeting autophagy to enhance immune checkpoint inhibition$445,954
P50 · FY2022 · CA · contact PI
Cancer Therapeutics Program$84,880
P30 · FY2022 · CA · contact PI
SPORE in Skin Cancer$2,323,912
P50 · FY2021 · CA
Targeting PPT1 in the Tumor Microenvironment$483,340
P01 · FY2021 · CA · contact PI
Targeting autophagy to enhance immune checkpoint inhibition$470,485
P50 · FY2021 · CA · contact PI
Cancer Therapeutics Program$83,107
P30 · FY2021 · CA · contact PI
Targeting PPT1 in the Tumor Microenvironment$389,391
P01 · FY2020 · CA · contact PI
Cancer Therapeutics Research Program$77,523
P30 · FY2020 · CA · contact PI
Targeting PPT1 in the Tumor Microenvironment$482,190
P01 · FY2019 · CA · contact PI
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy$355,019
R01 · FY2019 · CA · contact PI
Cancer Therapeutics Research Program$77,593
P30 · FY2019 · CA · contact PI
Cancer Therapeutics Research Program$7,213
P30 · FY2019 · CA · contact PI
Cancer Therapeutics Research Program$5,768
P30 · FY2019 · CA · contact PI
Cancer Therapeutics Research Program$3,627
P30 · FY2019 · CA · contact PI
Cancer Therapeutics Research Program$1,106
P30 · FY2019 · CA · contact PI
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy$366,000
R01 · FY2018 · CA · contact PI
Autophagy Modulation for Melanoma Therapy$330,885
P50 · FY2018 · CA · contact PI
Cancer Therapeutics Research Program$155,631
P30 · FY2018 · CA · contact PI
Cancer Therapeutics Research Program$9,404
P30 · FY2018 · CA · contact PI
Cancer Therapeutics Research Program$2,510
P30 · FY2018 · CA · contact PI
Cancer Therapeutics Research Program$2,143
P30 · FY2018 · CA · contact PI
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy$366,000
R01 · FY2017 · CA · contact PI
Autophagy Modulation for Melanoma Therapy$328,284
P50 · FY2017 · CA · contact PI
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition$312,942
R01 · FY2017 · CA · contact PI
Cancer Therapeutics Research Program$73,099
P30 · FY2017 · CA · contact PI
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy$366,000
R01 · FY2016 · CA · contact PI
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition$312,942
R01 · FY2016 · CA · contact PI
Autophagy Modulation for Melanoma Therapy$274,306
P50 · FY2016 · CA · contact PI
Cancer Therapeutics Research Program$72,887
P30 · FY2016 · CA · contact PI
Molecular mechanisms of BRAF inhibitor induced UPR and autophagy$366,000
R01 · FY2015 · CA · contact PI
Autophagy Modulation for Melanoma Therapy$321,594
P50 · FY2015 · CA · contact PI
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition$312,942
R01 · FY2015 · CA · contact PI
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition$332,350
R01 · FY2014 · CA · contact PI
Autophagy Modulation for Melanoma Therapy$320,283
P50 · FY2014 · CA · contact PI
HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition$423,754
R01 · FY2013 · CA · contact PI
Therapeutic approaches that target cancer cell metabolism$137,295
K23 · FY2012 · CA · contact PI
Therapeutic approaches that target cancer cell metabolism$137,295
K23 · FY2011 · CA · contact PI
Therapeutic approaches that target cancer cell metabolism$137,295
K23 · FY2010 · CA · contact PI
Autophagy inhibition as a therapeutic strategy for glioblastoma mutliforme$356,164
R21 · FY2009 · CA · contact PI
Autophagy inhibition as a therapeutic strategy for glioblastoma mutliforme$311,698
R21 · FY2009 · CA · contact PI
Therapeutic approaches that target cancer cell metabolism$137,295
K23 · FY2009 · CA · contact PI
Autophagy inhibition as a therapeutic strategy for glioblastoma mutliforme$369,053
R21 · FY2008 · CA · contact PI
Therapeutic approaches that target cancer cell metabolism$137,295
K23 · FY2008 · CA · contact PI